Biotech/Biopharma Investment for Family Offices, Funds or Focused Investors

I posted some months ago as I've been advising a Biotech/Biopharma company that has spent the last 5 years developing a groundbreaking and now patented drug delivery platform. Two companies have sub-licensed the platform in the diabetes management and oncology spaces. Base on trials to date, both companies seem to have blockbuster potential. They've made great progress and developed some key partnerships recently. Each is now raising $10M in Seed funding which will go towards NHP trials, building up the management team, preparing for IND, starting fast-track FDA approval process and engaging a Big Pharma partner. An early exit expected (~18 months) with sizable return opportunity. Email me at redacted for more details and to set up a chat.